Literature DB >> 15228396

Primary immunodeficiency diseases in adulthood.

D S Riminton1, S Limaye.   

Abstract

Occasionally, patients present with clinical episodes of infectious disease that seem to fall beyond the scope of normal immunocompetence. Examples include infections that are unusually persistent, recurrent or resistant to treatment, or those involving unexpected dissemination of disease or atypical pathogens. Recent cellular and molecular advances in immunology help to inform the investigation and management of these cases and provide opportunities for family surveillance and disease prevention. More than 100 separate primary (inherited) immunodeficiency disease (PID) states have now been defined, each with a range of syndromic manifestations. Many of these are rare diseases of childhood, but some, either in atypical or attenuated forms, emerge for the first time in adulthood. We outline a diagnostic approach to five groups of PID presenting in adulthood and describe the recently launched web-based PID Register of Australia and New Zealand--a new mechanism for improving knowledge and service delivery to Australasian patients and their clinical carers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228396     DOI: 10.1111/j.1445-5994.2004.00599.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  6 in total

1.  Primary immune deficiencies presenting in adults: seven years of experience from Iran.

Authors:  Davood Mansouri; Parisa Adimi; Mehdi Mirsaedi; Nahal Mansouri; Payam Tabarsi; Majid Amiri; Hamid R Jamaati; Masoud Motavasseli; Noushin Baghaii; Ali Cheraghvandi; Reza Rouhi; Navid A Roozbahany; Soheila Zahirifard; Forouzan Mohammadi; Mohammad R Masjedi; Ali A Velayati; Jean L Casanova; David P Speert; R Kevin Elwood; Robert Schellenberg; Stuart E Turvey
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

2.  Immune globulin subcutaneous (human) vivaglobin: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

3.  An immune globulin intravenous (human), 10% liquid privigen: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

4.  Tuberculosis and the risk of infection with other intracellular bacteria: a population-based study.

Authors:  M A Huaman; C T Fiske; T F Jones; J Warkentin; B E Shepherd; L A Ingram; F Maruri; T R Sterling
Journal:  Epidemiol Infect       Date:  2014-08-22       Impact factor: 2.451

5.  Disseminated bronchiectasis in an adult with common variable immunodeficiency.

Authors:  Andrés Felipe Zea-Vera; Olga Lucia Agudelo-Rojas
Journal:  Colomb Med (Cali)       Date:  2015-03-30

6.  Does the proper intravenous immunoglobulin substitution in primary immunodeficiency protect against HBV infections?: a description of a case series.

Authors:  Glück Joanna; Zeglen Slawomir; Rymarczyk Barbara; Rogala Barbara
Journal:  Med Microbiol Immunol       Date:  2008-04-08       Impact factor: 3.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.